Dr. Christopher Ryan Henry, MD

Dr. Henry practices at Retina Consultants of Houston in Bellaire, Texas.

Dr. Henry's NPI, 1881837995, was assigned on April 20, 2009. Dr. Henry graduated from Medical College Of Wisconsin in 2009. Dr. Henry holds Texas license Q5426.

Dr. Henry's primary practice is Retina Consultants of Houston, at 6300 W S Loop, Bellaire, TX 77401 in Harris County. The practice phone is (713) 524-3434.

Dr. Henry's primary practice is Retina Consultants of Houston in Bellaire, Texas. Dmand AI also links Dr. Henry to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Henry practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Henry's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Henry is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Henry's licenses on file in 2 states: Texas and Florida.

Dmand AI lists age-related macular degeneration, cataract, cold sores or genital herpes, conjunctivitis, dry eye, eyelid inflammation, glaucoma and hereditary corneal conditions among the conditions Dr. Henry treats.

CMS data shows 9,396 Medicare services from Dr. Henry across 14 procedure codes in 2024, for 625 Medicare patients. Medicare paid $2,067,195 for them. Every service was in an office.

CMS counts 625 Medicare patients who saw Dr. Henry in 2024. The largest group is 65 to 74, with 258 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Henry's median patient age at 69, with 54% women.

In 2024, Dr. Henry wrote 1,104 Medicare Part D claims for 229 patients. 67% of them were for generic drugs. CMS names the drug for 987 of them, across 16 drugs with 11 or more claims each, at $41,322 in total drug cost. In 2023, CMS named 946 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Henry for performance year 2024, reported as part of a group. Dr. Henry accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 52 papers to Dr. Henry, published from 2005 to 2024. 2020 was the busiest year, with 4. The most frequent topics are Tomography, Optical Coherence, Visual Acuity and Vitrectomy. Dr. Henry has published most often in Ophthalmology. Dr. Henry's most frequent co-authors are Harry W. Flynn, MD, Janet L. Davis, MD and Thomas Anthony Ciulla, MD.

Dmand AI links Dr. Henry to 4 clinical trials, 4 of them phase 2 studies. Conditions studied include Diabetic Retinopathy and Diabetic Angiopathies. Greater Houston Retina Research sponsors the most, 2.

CMS Open Payments shows 219 general payments to Dr. Henry from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Genentech, Inc. paid the most, $16,797.

Dmand AI lists 3 awards for Dr. Henry, most recently Heed Ophthalmic Foundation Fellowship Award in 2015.

Dr. Henry graduated from Medical College Of Wisconsin in 2009. Dr. Henry is a member of AOA, AAO, ASRS and TMA.

Dr. Henry is in network with 23 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.